Story
J.P. Morgan Lifts Novo Nordisk Price Target on Strong Ozempic, Wegovy Sales

J.P. Morgan has increased its December 2027 price target for Novo Nordisk (NVO) to 275 Danish crowns from a previous 250 crowns, attributing the revision to stronger sales forecasts for its blockbuster diabetes and weight-loss drugs. In a note published Tuesday, the bank maintained its “neutral” rating on the pharmaceutical giant's stock.
Revised Forecasts
The analyst's optimism is rooted in Novo Nordisk's second-quarter 2026 financial results. J.P. Morgan raised its 2026 sales forecast for the company by 5%, citing several key factors:
- Ozempic: The forecast for Ozempic sales in 2026 was increased by 8% to 113 billion crowns. This is due to slower-than-expected generic competition and favorable U.S. gross-to-net price adjustments.
- Wegovy: The forecast for the injectable weight-loss drug was lifted by 7% to 82 billion crowns, driven by robust growth in markets outside the United States.
Looking further ahead, J.P. Morgan increased its 2027-2030 sales forecasts by 6-7% and its adjusted earnings per share (EPS) estimates for 2026-2030 by 4-8%.
A Muted Growth Outlook
AdDespite the upward revisions for its key products, the bank projects a relatively flat top-line for Novo Nordisk in 2026 at constant exchange rates, followed by modest growth of approximately 1% in 2027 and 2% in 2028.
This tempered outlook is partially due to a downward revision for Oral Wegovy, with its 2026 forecast cut by 11% to 18 billion crowns on signs of slowing launch momentum in the U.S. Furthermore, J.P. Morgan expects growth in 2027 to be offset by a decline in Ozempic sales, which will face pressure from volume loss and anticipated price cuts under the U.S. Inflation Reduction Act.
Valuation Basis
The new price target of 275 DKK is based on a valuation of 12 times the bank's estimated 2027 adjusted EPS. According to the note, this multiple represents a roughly 20% discount to the broader pharmaceutical sector. Future growth acceleration beyond 2028 is seen as highly dependent on the company's pipeline, particularly the development of its next-generation oral drug, zenagamtide.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.